openPR Logo
Press release

Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercially Available Biosimilar Insulin In Markets

07-08-2017 01:51 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global Biosimilar Insulin Market To Witness Exponential Growth

“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of biosimilar insulin market.

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-biosimilar-insulin-market-opportunity-and-clinical-insight-outlook-2022.php

Report Table of Contents

Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development

Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin

Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact of Insulin Resistance in Diabetes 2

Engineering of Synthetic Insulin
4.1 Production of Human Insulin
4.2 Categorization of Insulin and Its Analogues
4.2.1 Rapid Acting Insulins
4.2.2 Short Acting Insulins
4.2.3 Intermediate Insulin
4.2.4 Long Lasting Insulins

Insulinotherapeutics in Diabetes
5.1 Conventional Insulinotherapy
5.2 Flexible or Intensive Insulinotherapy

Global Economic Aspects of Insulin
6.1 Skyrocketing Cost of Insulin Therapies
6.2 Emergence of Biosimilar

Global Economic Cost of Diabetes
7.1 Monetary Burden of Diabetes
7.2 US
7.3 Europe
7.4 Japan
7.5 China
7.6 India

Global Aspects of Biosimilar Insulins
8.1 US
8.2 Europe
8.3 Japan
8.4 Asia (Excluding Japan)

Global Biosimilar Insulin Market Overview
9.1 Preface to Biosimilar Insulin Market
9.2 Biosimilar Competition Assessment

Global Biosimilar Insulin Clinical Pipeline Insight

Marketed Biosimilar Insulin Clinical Insight by Company, Indication and Phase
11.1 Insulin Biosimilar (Wosulin-R)
11.2 Insulin Glargine Biosimilar (Glaritus, Glaritus Cart, Glaritus DispoPen)
11.3 Insulin Glargine Biosimilar (Abasaglar, Abasria and Basalgar)
11.4 Insulin Suspension Isophane/Insulin Biosimilar (Jusline 30/70)
11.5 Insulin Glargine Biosimilar (Basalog and GALACTUS)
11.6 Insulin Suspension Isophane Biosimilar (Jusline N)
11.7 Insulin Suspension Isophane/Insulin Biosimilar (Insulin H Mix)
11.8 Insulin Suspension Isophane Biosimilar (Insulin Hbio NPH)
11.9 Insulin Biosimilar (Insulin Hbio R)
11.10 Insulin Glargine Biosimilar (Basalin)
11.11 Insulin/Insulin Suspension Isophane Biosimilar (Wosulin 30/70, 50/50)
11.12 Insulin Suspension Isophane Biosimilar (Wosulin-N)
11.13 Insulin Biosimilar (Jusline R)
11.14 Insulin Glargine Biosimilar (Basugine)
11.15 Insulin Biosimilar (Insugen)

Biosimilar Insulin Future Targeted Market
12.1 Global High Prevalence of Diabetics
12.2 Global Prevalence of Obesity

Global Biosimilar Insulin Market Dynamics
13.1 Accelerating Parameters
13.2 Major Challenges of Biosimilar Insulin Market

Future Implications of Biosimilar Insulin

Competitive Landscape
15.1 Biocon
15.2 Biogenomics
15.3 Eli Lilly
15.4 GanandLee Pharmaceuticals
15.5 Geropharm
15.6 Julphar Gulf Pharmaceutical Industries
15.7 Paras Biopharmaceuticals
15.8 Samsung Bioepis
15.9 Sedico
15.10 Wockhardt

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercially Available Biosimilar Insulin In Markets here

News-ID: 615052 • Views: 991

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Insulin

Insulin Patch Pumps Market Report 2018: Segmentation by Insulin Type (Bolus Insu …
Global Insulin Patch Pumps market research report provides company profile for Roche Holding AG, Cellnovo Group SA, Spring Health Solution Ltd., Debiotech, CeQur SA, Valeritas, Becton Dickenson & Company, Insulet Corporation, Johnson & Johnson, Medtrum Technologies Inc. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue,
Bluetooth connected smart insulin pens represent the future of insulin delivery …
Increasing pool of diabetic patients witnessed across the globe has prompted leading manufacturers of medical devices towards development of ground-breaking products. Smart insulin pens are among such devices that have revolutionised the global market for diabetic injection pens. A recent study published by Future Market Insights projects that the global smart insulin pens market, which is currently valued at US$ 0.86 Mn, will expand vigorously at 17.9% CAGR through the
Insulin pump Market Explore Future Growth 2018-2026 by Global Type-Traditional i …
Insulin pump is a portable device attached to the body that continuously delivers preset amounts of short or rapid acting insulin in the body to control diabetes. Insulin therapy is required in type 1 diabetes and sometime in type 2 diabetes. It serves as an effective alternative to insulin injections. Furthermore, insulin pump delivers the insulin according to the need of body as basal rate, where small amount of insulin
Insulin Drug and Delivery Technologies Market Report 2018: Segmentation by Produ …
Global Insulin Drug and Delivery Technologies market research report provides company profile for Julphar, Ypsomed, Becton, Dickinson and Company, Sanofi, Eli Lilly and Company, Biocon and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc.
09-06-2017 | Health & Medicine
MRRSE
Smart Insulin Pens Market: Bluetooth Connected Smart Insulin Pens Allow Effectiv …
By connectivity, the Bluetooth connected smart insulin pen segment is expected to account for a value share of US$ 0.276 Mn in 2017. The segment is expected to reach a little more than US$ 2 Mn by 2027 end, registering the highest CAGR of 23.2% over the forecast period. Bluetooth connected smart insulin pens represent the future of insulin delivery devices. Such devices have an inbuilt Bluetooth connectivity feature allowing
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact